20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics · page 6 of 7

Topic	Participants	Replies	Views	Activity
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide randomised trial preprint effect size retatrutide Solved Closed On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+12	16	50k	12mo
Ipamorelin selectivity claims and where they came from Compounds › Secretagogues & GH axis GHRP class tesamorelin ipamorelin Closed Ipamorelin selectivity claims and where they came from — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+51	56	8.8k	12mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…	+48	53	31k	13mo
Revisiting: Food effects on oral incretin absorption: what is documented Compounds › Oral incretins oral semaglutide PIONEER programme SOUL trial orforglipron Under review Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…	+6	10	51k	13mo
Coming back to: Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide SELECT trial randomised trial STEP programme Asking directly, because I could not find a straight answer: Why semaglutide solutions can look faintly opalescent and when that matters Comparing SELECT ( N Engl J Med , 2023) with PIONEER 6 ( N Engl J Med ,…	+16	20	17k	13mo
Why plausible mechanism is not evidence of effect — one year on Compounds › Repair & healing peptides needs a source preprint BPC-157 Solved Closed The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read…	+3	7	3.6k	13mo
Why plausible mechanism is not evidence of effect Compounds › Repair & healing peptides TB-500 preprint observational data Solved Closed Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is much…	+14	18	57k	13mo
Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues effect size randomised trial cagrilintide cagrisema Solved Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…	+128	142	38k	13mo
Second pass at: Semaglutide and alcohol: what is actually documented Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…	+15	19	4.4k	13mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…	+64	71	2.5k	13mo
The CagriSema phase 2 paper and what a fixed combination buys — the long version Compounds › Cagrilintide & amylin analogues amylin analogues cagrisema cagrilintide The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…	+137	158	17k	13mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
Why oral semaglutide needs an absorption enhancer at all — what changed since Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Solved Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it before…		2	61k	14mo
Follow-up: Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues cagrilintide cagrisema amylin analogues effect size Solved Under review Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…		2	41k	14mo
What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide STEP programme type 2 diabetes randomised trial Solved Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+120	132	2k	14mo
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Compounds › Secretagogues & GH axis CJC-1295 needs a source tesamorelin observational data Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with…	+63	68	18k	14mo
Ipamorelin selectivity claims and where they came from — a second dataset Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin ipamorelin Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021)…		2	27k	14mo
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Compounds › Secretagogues & GH axis GHRP class ipamorelin tesamorelin Under review The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N…	+60	64	25k	15mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+23	27	7.7k	15mo
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…	+154	165	6.3k	15mo
Retatrutide dose escalation in the published trials Compounds › Retatrutide preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…	+149	159	30k	15mo
Why cagrilintide alone is discussed so much less than in combination Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema Solved Closed Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+93	108	35k	16mo
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Compounds › Semaglutide STEP programme randomised trial SELECT trial type 2 diabetes Solved Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Session topic: SURMOUNT-1 ( N Engl J Med ,…	+112	130	2.2k	16mo
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…	+109	125	2k	16mo
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Compounds › Semaglutide STEP programme type 2 diabetes randomised trial effect size Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+125	132	39k	16mo
SNAC and the mechanism of oral peptide absorption — the long version Compounds › Oral incretins oral semaglutide randomised trial orforglipron SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+32	36	6.8k	16mo
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 needs a source Closed GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…	+9	13	249	17mo
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Compounds › Retatrutide effect size randomised trial TRIUMPH programme Solved Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med…		2	103	17mo
SNAC and the mechanism of oral peptide absorption Compounds › Oral incretins orforglipron randomised trial PIONEER programme oral semaglutide On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…	+13	17	14k	17mo
What we do not know about retatrutide, listed explicitly Compounds › Retatrutide retatrutide effect size preprint TRIUMPH programme The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024) with SURMOUNT-OSA…	+106	113	4.8k	17mo